Living donor renal transplantation with incidental renal cell carcinoma from donor allograft

Transplant International

Volumn 28, Issue 9, 2015, Pages 1126-1130

  Lugo Baruqui, Jose A ^a,b   Guerra, Giselle ^a,b   Chen, Linda ^a,b   Burke, George W ^a,b   Gaite, Judith A ^a   Ciancio, Gaetano ^a,b  

^a Florida   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

kidney; living donor; renal cell carcinoma

Indexed keywords

BASILIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; BK VIRUS INFECTION; CANCER STAGING; CASE REPORT; DIALYSIS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HAND ASSISTED LAPAROSCOPY; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENTAL FINDING; KIDNEY CARCINOMA; KIDNEY TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; MALE; PAPILLARY CARCINOMA; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; TUMOR CLASSIFICATION; CARCINOMA, RENAL CELL; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; GRAFT SURVIVAL; HOSPITAL ADMISSION; KIDNEY FAILURE, CHRONIC; KIDNEY NEOPLASMS; LAPAROSCOPY; MIDDLE AGED; NEPHRECTOMY; RADIOGRAPHY; RECURRENT DISEASE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; INCIDENTAL FINDINGS; KIDNEY FAILURE, CHRONIC; KIDNEY NEOPLASMS; KIDNEY TRANSPLANTATION; LAPAROSCOPY; LIVING DONORS; MALE; MIDDLE AGED; NEPHRECTOMY; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; WAITING LISTS; YOUNG ADULT;

EID: 84938746454     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12594     Document Type: Article

References (16)

1. Organ Procurement and Transplantation Network (OPTN), U.S. Transplants performed January 1988-January 2014, Health Resources and Services Administration, http://optn.transplant.hrsa.gov/, Last access April 12th, 2014.
2. Ljungberg B, Bensalah K, Bex A, et al,. Guidelines on renal cell carcinoma. Arnhem (The Netherlands): European Association of Urology (EAU), 2013: 56 pp.
3. Friedersdorff F, Roller C, Manus P, et al,. Fate of finally transplanted deceased donor kidneys initially rejected at other kidney transplantation centers. Urol Int 2014; 93: 474.
4. Maggiore U, Cravedi P,. The marginal kidney donor. Curr Opin Organ Transplant 2014; 19: 372.
5. Flechner SM, Campbell SC,. The use of kidneys with small renal tumors for transplantation: who is taking the risk? Am J Transplant 2012; 12: 48.
6. Desai R, Collett D, Watson CJ, Johnson P, Evans T, Neuberger J,. Estimated risk of cancer transmission from organ donor to graft recipient in a national transplantation registry. Br J Surg 2014; 101: 768.
7. Musquera M, Pérez M, Peri L, et al,. Kidneys from donors with incidental renal tumors: should they be considered acceptable option for transplantation? Transplantation 2013; 95: 1129.
8. Nicol D, Fujita S,. Kidneys from patients with small renal tumours used for transplantation: outcomes and results. Curr Opin Urol 2011; 21: 380.
9. Buell JF, Hanaway MJ, Thomas M, et al,. Donor kidneys with small renal cell cancers: can they be transplanted? Transplant Proc 2005; 37: 581.
10. Nalesnik MA, Woodle ES, Dimaio JM, et al,. Donor-transmitted malignancies in organ transplantation: assessment of clinical risk. Am J Transplant 2011; 11: 1140.
11. Rabbani F, Herr HW, Almahmeed T, Russo P,. Temporal change in risk of metachronous contralateral renal cell carcinoma: influence of tumor characteristics and demographic factors. J Clin Oncol 2002; 20: 2370.
12. Guidance for Developing and Implementing Procedures to Collect Post-Donation Follow-up Data from Living Donors, Developed by the OPTN/UNOS Living Donor Committee, Revised and Updated 2013
13. Hernández D, Martínez D, Gutiérrez E, et al,. Clinical evidence on the use of anti-mTOR drugs in renal transplantation. Nefrologia 2011; 31: 27.
14. Motzer RJ, Escudier B, Oudard S, et al,. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449.
15. Monaco AP,. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 2009; 87: 157.
16. Manuelli M, De Luca L, Iaria G, et al,. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation. Transplant Proc 2010; 42: 1314.